NCCN Updates 2024-2025 Multiple Myeloma Guidelines: Quadruplet Therapy and Immunotherapy Take Center Stage
Key Insights
NCCN (search) guidelines now recommend quadruplet regimens as the standard of care for newly diagnosed multiple myeloma (search) patients, supported by phase 3 trial data showing improved outcomes over triplet therapies.
Major updates to relapsed/refractory disease treatment include expanded integration of immunotherapy, with CAR T-cell therapies recommended in earlier treatment lines and clearer guidance on bispecific antibodies (search).
The guidelines provide enhanced recommendations for maintenance therapy with two-drug regimens and updated diagnostic approaches for smoldering myeloma (search) management.
The National Comprehensive Cancer Network (NCCN (search)) has unveiled significant updates to its multiple myeloma (search) treatment guidelines for 2024-2025, marking a paradigm shift in disease management with the adoption of more intensive combination therapies and novel immunotherapeutic approaches.
Quadruplet Therapy Emerges as New Standard
In a major advancement for newly diagnosed patients, quadruplet regimens have been established as the standard of care for both transplant-eligible and transplant-ineligible populations. "We restructured the approach," explains Dr. Shaji Kumar, research chair of the Division of Hematology at Mayo Clinic. This change is backed by multiple phase 3 trials demonstrating superior outcomes compared to traditional triplet therapies.
Enhanced Focus on Immunotherapy
The guidelines feature substantial revisions for relapsed and refractory multiple myeloma (search) treatment, with immunotherapy taking a more prominent role. The update includes comprehensive guidance on three available bispecific antibodies (search) and two approved CAR T-cell therapies. Notably, CAR T-cell therapy is now recommended for earlier lines of treatment, particularly for high-risk relapsed patients.
Personalized Maintenance Approaches
The updated guidelines introduce more nuanced recommendations for maintenance therapy, incorporating two-drug regimens in specific clinical scenarios. These recommendations are tailored based on individual patient characteristics and supported by phase 3 trial data, reflecting a move toward more personalized treatment approaches.
Smoldering Myeloma Management
Diagnostic approaches have been refined to address early intervention in smoldering myeloma (search). The revisions provide enhanced clarity on management strategies and incorporate emerging clinical evidence, offering clinicians more detailed guidance for this precursor condition.
The comprehensive updates reflect the rapidly evolving landscape of multiple myeloma (search) treatment, with a clear emphasis on more intensive initial therapy and the strategic integration of immunotherapeutic approaches. These changes are expected to significantly impact clinical practice and potentially improve patient outcomes across different disease stages.